Skip to content

July 17th, 2015: “EURETINA-Brief”© Issue No. 113

by Dr. Gearóid Tuohy


Dear EURETINA Members,


A very warm welcome to the July 17th, 2015 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue our delivery of up to date summary briefs on a range of topics of interest to retinal specialists and researchers across Europe. This resource is designed to accommodate the very busy schedules of all our members by providing them with a short overview of some new developments and announcements in our field over recent weeks.


As in previous issues we have incorporated a feedback section where you can comment on any of the news items or articles under discussion and we very much welcome all contributions. Previous articles and issues can be found in the archive section on the left hand panel.


The current issue highlights a number of research activities, clinical milestones and business developments in our field, including research led by clinicians at the University of Alberta, Canada on initiation of a Phase II clinical trial of a novel gene therapy for the treatment of choroideremia (CHM); publication by an expert panel of clinical ophthalmologists on the administration of aflibercept (Eylea) in wet age-related macular degeneration (AMD) after year 1 and; an announcement from Shire plc (LSE: SHP, NASDAQ: SHPG) and the US Foundation Fighting Blindness (FFB) highlighting a new initiative to accelerate the development of therapies that could treat autosomal dominant retinitis pigmentosa (adRP).


Finally, our feature bio-ophthalmology article reports on US-based research highlighting the rescue of a retinal degeneration by the reprogramming of rods into cones. The study used a well-characterized retinal transcription factor to re-direct rods to a cone cell fate. The result of the cellular reprogramming reduced rod photoreceptor cell death in a rhodopsin knock-out model of retinitis pigmentosa (RP). The results of the research, notwithstanding the loss of rod cell function and potential consequent night-blindness, suggest that maintaining a rod photoreceptor cell architecture may be sufficient to slow or halt cone cell degeneration.


As always, increased interaction by you with the EURETINA web community serves to expand your professional network and keep you up to date with the latest initiatives, activities and research in your field. Our hope is that such cross-fertilisation in an active web-based platform will lead to increased collaborative opportunities and ultimately to improved patient care. All readers are invited to submit comments or responses to any of the stories featured and we look forward to hearing from you over the coming month.


Best wishes,


Dr. Gearóid Tuohy, EURETINA